PROVIDER ALERT

Legacy Pharmaceutical Packaging, LLC – Losartan Potassium Tablets Drug Recall Notification

To:	Alliance Contracted Pharmacies	**Recall Class:**	*Not yet classified*
From:	Alliance Pharmacy Services Department	**Recall Issue Date:**	03/15/2019
Date:	04/29/2019	**Recall #:**	*Not yet classified*
Subject:	**DRUG RECALL NOTICE**	**Manufacturer**:	Legacy Pharmaceutical Packaging, LLC
Products:	Medi-Cal, Group Care	**Reason:**	Impurity or contaminant detection

DRUG AFFECTED	NDC	LOT #	EXPIRATION DATE
Losartan Potassium Tablets, USP 50 mg – 30-count	68645-494-54	**180190**	10/2020
Losartan Potassium Tablets, USP 50 mg – 30-count	68645-494-54	**180191**	10/2020
Losartan Potassium Tablets, USP 50 mg – 30-count	68645-494-54	**181597**	02/2021

Source: **www.fda.gov/Safety/Recalls/ucm633671.htm**

Image above reflects an example of recalled drug.

Questions? Please call the Alliance Pharmacy Services Department
Monday – Friday, 8 am – 5 pm
Phone Number: **1.510.747.4541**
www.alamedaalliance.org

Legacy Pharmaceutical Packaging, LLC has issued a recall of **three (3)** repackaged lots of **Losartan Tablets, USP 50 mg** to the consumer level. This recall was prompted due to Torrent Pharmaceuticals, Ltd. recent voluntary nationwide recall of Losartan Tablets, USP due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs, Ltd. Legacy Pharmaceutical Packaging, LLC has advised that NMBA is a potential human carcinogen. To date, Legacy has not received any reports of adverse events related to this recall.

Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Any general questions regarding the return of this product should be directed to:

Inmar Pharmaceutical Services
Monday – Friday, 9 am – 5 pm (EST)
Toll-Free: **1.877.538.8443**

Consumers, pharmacies, and healthcare facilities that have the recalled product should stop using and dispensing immediately.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA MedWatch Adverse Event Reporting program either online, by regular mail or by fax:

- **Online**: Complete and submit the report at **www.fda.gov/medwatch/report.htm**
- **Regular Mail or Fax**:
  - Download the form at **www.fda.gov/MedWatch/getforms.htm**
  - To request a reporting form, please call toll-free at **1.800.332.1088**
  - Please complete and return to the address on the pre-addressed form, or submit by fax to **1.800.FDA.0178 (1.800.332.0178)**